Single-dose test to tell if an injured peripheral nerve is still connected
A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma
A single medication dose could quickly show whether a damaged peripheral nerve is still intact for people with recent traumatic nerve injuries.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11178684 on NIH RePORTER |
What this research studies
If you've had a recent traumatic peripheral nerve injury, this work aims to give one dose of a drug that can briefly boost nerve signaling so clinicians can tell if the nerve remains connected. After the dose, doctors will perform bedside tests and electrodiagnostic measures to look for temporary return of function that indicates continuity. That information would help guide whether immediate surgery is needed or whether the nerve can be left to heal on its own. The approach repurposes drugs that enhance nerve conduction as a short-term diagnostic tool rather than a long-term treatment.
Who could benefit from this research
Good fit: People with recent traumatic peripheral nerve injuries (for example from accidents, battlefield wounds, or surgical injury) who can come to clinic soon after the injury are the ideal candidates.
Not a fit: Patients with long-standing nerve damage, purely central nervous system injuries, or diffuse neuropathies are unlikely to benefit from this one-dose peripheral-nerve continuity test.
Why it matters
Potential benefit: If successful, this could let doctors decide sooner who needs nerve repair surgery and who can avoid unnecessary operations, improving recovery and reducing harm.
How similar studies have performed: This is a novel application—related drugs have been used to enhance nerve signaling but have not been widely proven as a rapid one-dose diagnostic of nerve continuity.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Elfar, John — University of Arizona
- Study coordinator: Elfar, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.